Back to catalogue
№ 001 11 filings · 2021-06-03 → 2026-05-20

4BASEBIO PLC

4BB
Health Care Share price 475p Market cap £74m Overall fit 200 /1000

Poor fit for the AI-receiver mandate (no AI exposure), valuation is close to mid fair-value with downside skew from likely dilution, and downside protection is weak — operating leverage is real but only matters 2-3 years out.

Fair value range 350p–650p Mid case · £78m
Absolute upside +5.4% vs current market cap
Conviction 2/5 confidence in fair call
Supports the call
  • Clean balance-sheet disclosure
  • Small revenue base limits unit-economics ambiguity
  • Recent placing provides market-implied valuation anchor
Limits the call
  • Wide range of plausible 2027 revenue outcomes (£3-15m)
  • Near-certain dilution at unknown price before late-2027
Methodology

Forward EV/sales peer triangulation with dilution adjustment

In one line · bull case

Pure-play enzymatic synthetic-DNA platform with GMP licence and Tier 1 pharma validation, where high operating leverage could turn the loss equation if 2026-27 commercial conversion finally materialises.

In one line · biggest risk

Cash runway only into late-2027 against persistent £16m+ annual losses makes a heavily dilutive equity raise near-certain before the commercial story proves itself.

Drivers
AI beneficiary 15 /100
Synthetic-DNA CDMO with no demonstrable AI revenue line or AI-driven TAM expansion.
Operating leverage 75 /100
Heavily fixed admin cost base (£17.7m FY25) vs £1.7m revenue creates large dropthrough if revenue scales past £8-10m.
Earnings vs expectations 35 /100
Repeated program slippage; mRNA revenue from 2025 deferred into 2026+.
Growth momentum 60 /100
FY25 revenue +81%, Q4-25 pipeline +41% QoQ, GMP licence won — offset by repeated timeline slippage.
Moat 45 /100
33 patent families and differentiated enzymatic process — narrow but defensible vs Touchlight and Telesis Bio.
Earnings quality 30 /100
Persistent losses, capitalised R&D, share-based payment charges, FX noise; earnings yet to test cash conversion.
Management quality 40 /100
Founder CEO replaced Feb 2026; serial senior turnover; new team credentialled but unproven; Nov-24 placing now -65%.
Cyclicality 35 /100
Secular gene-therapy tailwind but exposed to biotech funding cycles and US health-policy shocks.
Leverage 55 /100
Drawn Deutsche Balaton facility plus other borrowings against £17.8m cash and persistent £16m+ annual cash burn.
Value-trap signals · 5
  • Revenue still under £2m after 5 years public despite repeated 'commercial inflection imminent' messaging
  • Nov-24 placing at £15/share — shares now -65% from that mark
  • Founder-CEO plus full C-suite turnover within 12 months
  • Material customer programs slipping from 2025 into 2026+
  • Ongoing Spanish IP litigation with Tyris Tx

4basebio PLC (4BB) — Research Note

Executive summary

4basebio is a Cambridge-based AIM-listed biotechnology company manufacturing enzymatically-produced synthetic DNA as a proprietary replacement for plasmid DNA used in gene therapies, mRNA vaccines, gene editing and viral vector programmes. Across the 2021-2025 period revenue grew from immaterial to £1.7m (FY25, +81% YoY) while losses widened to £16.9m and net cash fell from £34.6m to £17.8m after a £40m equity raise in Nov 2024 2026-05 final results; the share price has nearly halved over twelve months as commercial milestones slipped into 2026 and management was wholesale replaced. The single most important valuation point today: this is a speculative, pre-profitability story stock priced primarily on the option value of synthetic DNA displacing plasmid in clinical-grade manufacture — base-case fair value is uncomfortably close to the current price, and a further equity raise before late-2027 looks highly probable.

Fair value estimate

  • Fair value range: 350p – 650p per share (implied market cap range £54m – £101m), midpoint ~500p / £77.5m
  • Methodology: Forward EV/sales triangulated against synthetic-DNA / specialist CDMO peers. I assume 2027E revenue of £4-8m (anchored on FY25 £1.7m and the disclosed Q4-25 pipeline up 41% QoQ 2026-05 final results) and apply a 12-18x EV/sales multiple (early-stage life-sciences-tools peers like Telesis Bio trade <2x; the placing-implied valuation of £192m in Nov 2024 was 21x then-revenue 2025-05 final results). I deduct ~£20-30m of equity-raise dilution assumed before late-2027.
  • Vs. current £79.7m mcap (515p): mid-point implies ~3% downside; range spans -32% to +26%.

Sector context

Confirms as Health Care — life-sciences tools / synthetic biology CDMO. Quality / margin profile is well below typical scaled health-care peers: gross margin 57% (FY25), operating margin -1,040%, no positive EBITDA. Comparable listed peers: Telesis Bio (TBIO) — direct enzymatic-DNA competitor, also loss-making and small-cap; Touchlight (private, doggybone DNA) — closest commercial overlap; Oxford Biomedica, Catalent — larger gene-therapy CDMOs but very different scale.

Investment thesis

  • Clinical validation finally arriving — Tier 1 pharma dosing patients with opDNA®. A Tier 1 partner initiated Phase I/II dosing with mRNA built on 4BB's opDNA® template in October 2025, plus four IND/CTA programmes supported and 125+ customers 2026-05 final results. This is the proof-point the equity story has needed.
  • GMP licence + new commercial leadership materially shifts addressable revenue per customer. MHRA MIA IMP GMP certification in April 2025 unlocks supply of GMP drug substance into clinical trials — pre-GMP customers buy mg, GMP customers buy gram-to-kg with unit pricing orders of magnitude higher 2025-09 half-year + 2026-05 final results. New CEO Dr Walker and three other senior hires are CDMO scale-up veterans (Catalent, DSM, Patheon).
  • High operating leverage on a small revenue base. Admin costs of £17.7m are largely fixed across R&D, GMP infrastructure and patents (33 families). A £5-10m revenue base at 60%+ gross margin could close half the loss; the dropthrough is steep if pipeline conversion accelerates 2026-05 final results.

Key risks

  • Cash runway only into late-2027 — dilution looks unavoidable. £17.8m cash at year-end plus €7m Deutsche Balaton drawdown vs ~£16m annual cash burn means a raise will be needed before commercial inflection; the share is already down 54% YoY which would make a raise highly dilutive 2026-05 final results.
  • Major management exits / serial CEO change signal execution difficulty. Founder-CEO Lanckriet replaced February 2026; new CFO arrives July 2026; new COO and Exec Chair installed 2025-26 — wholesale C-suite turnover late in a commercial ramp is rarely benign 2026-05 final results.
  • Demand shocks in mRNA and US biotech funding. Filings explicitly cite "changes in US government health policy with respect to mRNA-based vaccines" softening that segment, NIH budget cuts and FDA leadership uncertainty deferring 2025 programs to 2026+ 2025-09 half-year + 2026-05 final results. Active Spanish litigation with Tyris Tx remains unresolved 2025-09 half-year.

Operating leverage

Operating leverage is structurally high but currently negative. FY25 admin expenses of £17.7m dwarf revenue of £1.7m and gross profit of £1.0m; the cost base is overwhelmingly fixed (scientific headcount, two UK sites + Spain + new US incorporation, GMP infrastructure, fixed R&D and patent legal). Gross margin held at 57% (FY25) vs 68% (FY24) on broadly stable mix — fully-burdened gross margins should rise toward 70-75% as GMP unit pricing rises. A revenue beat 10-20% above expectations is irrelevant at this scale; the real inflection is when revenue clears ~£8-10m, where existing infrastructure should produce >£4-5m of incremental gross profit dropping straight to operating loss reduction. The planned new Cambridge "innovation hub and manufacturing facility" in late summer 2026 will add fixed cost ahead of the revenue, so leverage will likely worsen before it improves 2026-05 final results. Genuine operating leverage would arrive in 2027-28 if pipeline conversion materialises.

Value-trap signals

  • Revenue still trivial after 5 years public despite repeated "commercial inflection imminent" messaging.
  • Equity issued at £15.00/share in Nov 2024 (mcap £192m); shares now trade 65% below that — value destruction for the most recent institutional investors.
  • Founder-CEO departure plus CFO, COO and Chair turnover in a 12-month window.
  • Material customer programs slipping from 2025 into 2026+ (mRNA vaccines) 2025-09 half-year.
  • Ongoing Spanish IP litigation 2025-09 + 2024-09 half-years.

Earnings vs. expectations

Filings disclose no analyst consensus and no quantitative management guidance to compare. Qualitative pattern: H1-2024 commentary promised significant 2024 revenue step-change against 2023's £0.5m — delivered £0.9m FY24, materially below the implicit ambition. H1-2025 results then guided to continued strong growth but explicitly acknowledged that mRNA programs originally expected in 2025 had slipped to 2026+ 2025-09 half-year. FY25 revenue of £1.7m (+81%) is the first delivery clearly framed as a beat against second-half-2025 expectations. Net: a pattern of pushed timelines rather than headline misses, with management messaging gradually re-calibrated to be more cautious in 2025-26 vs the optimism of 2022-24.

Conviction

Conviction: 2 / 5 (low).

  • Anchors: clean disclosure on cash/balance sheet; very small revenue base reduces ambiguity in unit economics; market-implied valuations exist (Nov 2024 placing) as a high-water reference.
  • Limits: extremely wide range of plausible 2027 outcomes (£3-15m revenue); near-certain dilution at an unknown price; new management team has not yet operated a full year; competing platforms (Touchlight, Telesis Bio) are also iterating.

Driver scoring

ai_beneficiary 15 — not an AI play. No demonstrable AI-driven revenue line, addressable market expansion, or AI proprietary-data moat. Genetic-medicine industry as a whole has some indirect AI design tailwinds but 4BB sells DNA manufacture, not AI-discovered drugs.

operating_leverage 75 — high fixed-cost base, gross margins improving, plenty of spare capacity. Big incremental dropthrough if revenue scales.

earnings_surprise_trend 35 — repeated timeline slippage; revenue ambitions consistently below early framing; management has had to re-set commercial messaging.

cyclicality 35 — secular tailwind from gene therapy / mRNA, but exposed to biotech funding cycles and government health-policy shocks (NIH budgets, FDA mRNA scrutiny).

moat 45 — 33 patent families and a differentiated enzymatic process give meaningful but not insurmountable protection; Touchlight and others have competing technologies.

leverage 55 — Deutsche Balaton facility now ~€7m drawn plus existing borrowings (£15.6m non-current liabilities) against £17.8m cash and persistent losses — heading toward financial stress before commercial breakeven.

earnings_quality 30 — meaningful loss-making, capitalised development costs growing (£4.8m intangibles), large non-cash and FX items, share-based payment charges.

management_quality 40 — founder CEO replaced; serial senior turnover; new team is credentialled but unproven in this seat. November 2024 placing at £15 with the share now at £5.15 reflects poor near-term capital allocation timing.

growth_momentum 60 — revenue +81% YoY and pipeline +41% Q3→Q4 give real momentum, offset by repeated program slippages.

overall_score: 200

Poor fit for this investor profile: no meaningful AI-receiver angle (the dominant weighting); valuation is close to my mid fair-value with downside skew given dilution risk; operating leverage is structurally attractive but only mattering 2-3 years out; downside protection is weak (cash burn, near-certain raise). The synthetic-DNA story is genuinely interesting but it's not what this portfolio is built to own.

Filings consulted · 12

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-20Final Results And Notice OF Agm2026-05-20_9576804_final-results-and-notice-of-agm.md1.00
  2. 2025-09-29Half Year Report2025-09-29_9153114_half-year-report.md0.77
  3. 2025-06-27Result OF Agm2025-06-27_8953072_result-of-agm.md0.26
  4. 2025-05-27Final Results And Notice OF Agm2025-05-27_8897306_final-results-and-notice-of-agm.md0.65
  5. 2024-09-27Half Year Report2024-09-27_8443424_half-year-report.md0.58
  6. 2024-06-28Result OF Agm2024-06-28_8285593_result-of-agm.md0.20
  7. 2024-06-05Final Results And Notice OF Agm2024-06-05_8242687_final-results-and-notice-of-agm.md0.45
  8. 2023-09-21Half Year Report2023-09-21_7768634_half-year-report.md0.41
  9. 2023-06-14Result OF Agm2023-06-14_7575114_result-of-agm.md0.14
  10. 2021-06-30Result OF Agm2021-06-30_6471811_result-of-agm.md0.07
  11. 2021-06-04Notice OF Agm And Posting OF Accounts2021-06-04_6615974_notice-of-agm-and-posting-of-accounts.md0.03
  12. 2021-06-03Final Results2021-06-03_6566665_final-results.md0.10

This research note was authored by a large language model after reading 11 regulatory filings published between 2021-06-03 and 2026-05-20. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.